FIG 1.

Maximum change from baseline in target lesions (A),^a time to response and response duration (B), and Kaplan-Meier estimate of DOR (C) based on blinded independent central review. ^aMaximum change from baseline in target lesions by central review was assessed for patients who received ≥ 1 dose of pembrolizumab, had baseline imaging with measurable disease per RECIST v1.1, and had a postbaseline assessment (n = 155). +, ongoing response; CR, complete response; DOR, duration of response; PD, progressive disease; PR, partial response.